PSMA and 18F-FDG PET Imaging in the Treatment of Metastatic Prostate Cancer with 223Ra: Initial Application and Experience
Objective To share our experience of the use of prostate specific membrane antigen (PSMA) and/or 18F-fluoroodexyglucose (18F-FDG) positron emission tomography (PET) in the setting of radium-223 dichloride (223Ra) in treatment of bone metastases of prostate cancer in order to broaden the know-ledge...
Main Authors: | HU Guilan, TIAN Jian, LI Yongqiang, JI Zhigang, HUO Li, CHEN Yonghui |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Office of Medical Journal of Peking Union Medical College Hospital
2023-07-01
|
Series: | Xiehe Yixue Zazhi |
Subjects: | |
Online Access: | https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2023-0152 |
Similar Items
-
Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT
by: Kalevi Kairemo, et al.
Published: (2015-10-01) -
Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer
by: Kazuya Takeda, et al.
Published: (2023-01-01) -
Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
by: Gayed I, et al.
Published: (2018-09-01) -
[223Ra] RaCl2 nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era
by: Yang Yang, et al.
Published: (2022-12-01) -
Radium 223 dichloride for prostate cancer treatment
by: Deshayes E, et al.
Published: (2017-09-01)